Clinical trial
A Phase 4, Open-Label, Single-Arm, 46-Week Study to Investigate the Safety and Efficacy With Tirzepatide in Adult Indian Participants With Either Type 2 Diabetes or Obesity
NCT07438444 is registered in ClinicalTrials.gov with Eli Lilly and Company as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 4, Open-Label, Single-Arm, 46-Week Study to Investigate the Safety and Efficacy With Tirzepatide in Adult Indian Participants With Either Type 2 Diabetes or Obesity
- Lead sponsor
- Eli Lilly and Company
- Phase
- Phase 4
- Overall status
- Active, not recruiting
- Start date
- February 27, 2026
- Completion date
- July 31, 2027
- Enrollment
- 344 (estimated)
- Sites
- 21
Conditions
As the registry lists them; a condition with its own page is linked.